MoonLake Immunotherapeuti... (MLTX)
MoonLake Immunotherapeutics Statistics
Share Statistics
MoonLake Immunotherapeutics has 63.28M shares outstanding. The number of shares has increased by 0.65% in one year.
| Shares Outstanding | 63.28M |
| Shares Change (YoY) | 0.65% |
| Shares Change (QoQ) | 0.35% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 52.78M |
| Failed to Deliver (FTD) Shares | 10.33K |
| FTD / Avg. Volume | 2.42% |
Short Selling Information
The latest short interest is 6.35M, so 10.03% of the outstanding shares have been sold short.
| Short Interest | 6.35M |
| Short % of Shares Out | 10.03% |
| Short % of Float | 24.2% |
| Short Ratio (days to cover) | 11.66 |
Valuation Ratios
The PE ratio is -0.03 and the forward PE ratio is -10.36. MoonLake Immunotherapeutics's PEG ratio is 0.
| PE Ratio | -0.03 |
| Forward PE | -10.36 |
| PS Ratio | 0 |
| Forward PS | 2 |
| PB Ratio | 0.01 |
| P/FCF Ratio | -0.03 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for MoonLake Immunotherapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 21.11, with a Debt / Equity ratio of 0.
| Current Ratio | 21.11 |
| Quick Ratio | 21.11 |
| Debt / Equity | 0 |
| Debt / EBITDA | - |
| Debt / FCF | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1.21B |
| Employee Count | 100 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -282.2M |
| Effective Tax Rate | 0.23% |
Stock Price Statistics
The stock price has increased by -2.44% in the last 52 weeks. The beta is 1.31, so MoonLake Immunotherapeutics's price volatility has been higher than the market average.
| Beta | 1.31 |
| 52-Week Price Change | -2.44% |
| 50-Day Moving Average | 39.49 |
| 200-Day Moving Average | 46.4 |
| Relative Strength Index (RSI) | 56.56 |
| Average Volume (20 Days) | 426.2K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | 0 |
| Net Income | -120.68B |
| EBITDA | 0 |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1919.51 |
Balance Sheet
The company has 180.43M in cash and 2.83M in debt, giving a net cash position of 177.6M.
| Cash & Cash Equivalents | 180.43M |
| Total Debt | 2.83M |
| Net Cash | 177.6M |
| Retained Earnings | -235.59B |
| Total Assets | 477.93B |
| Working Capital | 451.82B |
Cash Flow
In the last 12 months, operating cash flow was -116.59B and capital expenditures -519.52K, giving a free cash flow of -117.11B.
| Operating Cash Flow | -116.59B |
| Capital Expenditures | -519.52K |
| Free Cash Flow | -117.11B |
| FCF Per Share | -1862.67 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
MLTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for MLTX is $73, which is 82.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $73 |
| Price Target Difference | 82.4% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
Scores
| Altman Z-Score | 0.5 |
| Piotroski F-Score | 0 |